Hemophilia News and Research

RSS

Hemophilia is a rare, inherited bleeding disorder in which your blood doesn’t clot normally. If you have hemophilia, you may bleed for a longer time than others after an injury. You also may bleed internally, especially in your knees, ankles, and elbows. This bleeding can damage your organs or tissues and, sometimes, be fatal.

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

Baxter International Inc. today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.

From Baxter International Inc. 22 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

Victims of sudden cardiac arrest who are treated with automated external defibrillators by bystanders have a much greater chance of survival than their counterparts, according to landmark research by the Resuscitation Outcomes Consortium, just published in the Journal of the American College of Cardiology.

16 Apr 2010

PPA helps qualified patients save money on their medicines

As recently noted in the Queens Chronicle, a nationwide partnership, consisting of more than 475 public and private assistance programs, is helping qualified patients save money on their medicines.

16 Apr 2010

Boston Scientific receives FDA clearance to resume distribution of COGNIS CRT-Ds and TELIGEN ICDs

Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.

16 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

CSL Behring calls for grant requests through LEAD program

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

13 Apr 2010

Parents lack understanding of causes, signs and symptoms of dehydration in children

Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick - pointing to a greater need for awareness and education around the condition and its treatment.

From Baxter International Inc. 8 Apr 2010

FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery

Baxter International Inc. and Nycomed today announced the U.S. Food and Drug Administration (FDA) approval of TachoSil (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil is the first and only adjunctive hemostatic agent available in the U.S. that combines a collagen patch with a coating of human coagulation factors.

From Baxter International Inc. 7 Apr 2010

NYBC urges community to donate blood and save lives

New York Blood Center and its divisions serving the 20 million people of New York City, Long Island, the Hudson Valley, and New Jersey call upon the community to please donate blood, in recognition of World Health Day, and to help save lives.

2 Apr 2010

DSMB for DIGNITY trial recommends Celsion continue enrollment

Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.

31 Mar 2010

Plant-based system could help improve lives of hemophilic patients

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

30 Mar 2010

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Pain Therapeutics, Inc. today announced encouraging clinical data with PTI-188, an early-stage drug for metastatic melanoma. Metastatic melanoma is a lethal form of skin cancer in which patients typically have a median survival time of 9 months.

24 Mar 2010

NYBC joins "Honor Roll of Life" of US blood centers to support Haiti relief effort

New York Blood Center, serving New York City, Long Island, the Hudson Valley, and New Jersey, has provided a contribution of $76,250, and has joined the "Honor Roll of Life" of US blood centers providing units of blood directly to the Haiti relief effort.

20 Mar 2010

Novo Nordisk awarded funds to support diabetes summer camps nationwide

Novo Nordisk Inc., a world leader in diabetes care, announced that it has awarded funds to support scholarships and capital improvements to diabetes summer camps at fifteen locations nationwide. In support of their dedication to meeting the needs of children with diabetes, the grants will help the camps provide financial assistance programs to campers and improve facilities for the campers' use.

From Novo Nordisk 16 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.

From Baxter International Inc. 12 Mar 2010

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Baxter International Inc., in conjunction with DynPort Vaccine Company LLC, a CSC Company, today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.

From Baxter International Inc. 12 Mar 2010

Hemophilia News and Research

Further Reading

Baxter International's global sales for first-quarter advances by 11% to $3.1 billion

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Victims of SCA treated with AEDs by bystanders have much greater chance of survival

PPA helps qualified patients save money on their medicines

Boston Scientific receives FDA clearance to resume distribution of COGNIS CRT-Ds and TELIGEN ICDs

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

CSL Behring calls for grant requests through LEAD program

Parents lack understanding of causes, signs and symptoms of dehydration in children

FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery

NYBC urges community to donate blood and save lives

DSMB for DIGNITY trial recommends Celsion continue enrollment

Plant-based system could help improve lives of hemophilic patients

Patients switching to Victoza experience further reductions in A1c and weight loss

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

NYBC joins "Honor Roll of Life" of US blood centers to support Haiti relief effort

Novo Nordisk awarded funds to support diabetes summer camps nationwide

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Growing incidence of chronic kidney disease: Early detection and knowledge of treatment options vital

Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News